10-Q: Sonnet BioTherapeutics Reports Q1 2025 Financial Results and Provides Business Update
Sentiment:
Quarterly Report
Sonnet BioTherapeutics reports its financial results for the quarter ended December 31, 2024, and provides an update on its clinical programs and recent developments.
Delay expectedAfter some delays in 2024, activities will continue through 2025 with the potential to generate a drug suitable for preclinical studies and subsequent human studies.
Capital raiseThe company states that substantial additional financing will be needed by the Company to fund its operations.The company plans to secure additional capital in the future through equity or debt financings, including sales pursuant to its ChEF Purchase Agreement (the Purchase Agreement) with Chardan Capital Markets, LLC (Chardan), related to a ChEF, Chardans committed equity facility (the Facility); partnerships; collaborations; or other sources to carry out the Companys planned development activities.
Worse than expectedThe company's net losses increased significantly compared to the same period last year, indicating a worsening financial performance.
Summary
- Sonnet BioTherapeutics Holdings, Inc. is a clinical-stage, oncology-focused biotechnology company developing biologic medicines.
- The company's lead asset, SON-1010, is in clinical development for solid tumor indications.
- A collaboration agreement with Roche is in place for clinical evaluation of SON-1010 with atezolizumab in platinum-resistant ovarian cancer.
- Sonnet is expanding its Phase 1 SB101 clinical study of SON-1010 to evaluate its effect in combination with trabectedin.
- The company is advancing SON-080 in target indications of Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Diabetic Peripheral Neuropathy (DPN).
- Alkem Laboratories Limited will develop and commercialize SON-080 for DPN in India.
- SON-1210, a bifunctional construct, is being developed for solid tumor indications.
- A Phase 1b/2a study of SON-1210 in pancreatic cancer will be conducted by the Sarcoma Oncology Center (SOC).
- The company has completed sequence confirmation for SON-3015, but the development program is on hold for expense reduction purposes.
- Sonnet believes its cash of $4.9 million at December 31, 2024, will fund projected operations into July 2025.
- The company received preliminary approval to sell up to $0.8 million of its New Jersey state net operating losses.
- Net losses were $3.2 million for the three months ended December 31, 2024, compared to $1.2 million for the same period in 2023.
- Collaboration revenue was $1.0 million for the three months ended December 31, 2024, compared to $18,626 for the same period in 2023.
- Research and development expenses were $1.9 million for the three months ended December 31, 2024, compared to $0.6 million for the same period in 2023.
- General and administrative expenses were $2.0 million for the three months ended December 31, 2024, compared to $0.7 million for the same period in 2023.
- The company closed a public offering in November 2024 for net proceeds of $4.2 million.
- A registered direct and PIPE offering in December 2024 raised net proceeds of approximately $3.5 million.
- Jay Cross resigned as Chief Financial Officer, effective February 21, 2025, and Donald Griffith was appointed as his successor.
- Stephen McAndrew was appointed as Chief Business Officer, commencing February 17, 2025.
Sentiment
Score: 5
Explanation: The sentiment is neutral. While there are positive developments such as collaborations and recent funding, the increasing losses and the need for additional capital raise concerns about the company's financial stability.
Positives
- Collaboration revenue increased significantly due to the Alkem agreement, providing upfront payments and potential future milestones and royalties.
- The company secured $4.2 million in net proceeds from a public offering in November 2024.
- The company secured $3.5 million in net proceeds from a registered direct and PIPE offering in December 2024.
- The company received preliminary approval to sell up to $0.8 million of its New Jersey state net operating losses.
- The European Patent Office granted Patent No. EP3583125 B1, entitled Albumin Binding Domain Fusion Proteins, which covers our FHAB technology and includes therapeutic fusion proteins that utilize FHAB for tumor targeting and retention, and provide extended pharmacokinetics (PK).
Negatives
- The company has incurred recurring operating losses and negative cash flows since inception.
- The company's cash is expected to fund operations only into July 2025, raising concerns about its ability to continue as a going concern.
- Net losses increased to $3.2 million for the three months ended December 31, 2024, compared to $1.2 million for the same period in 2023.
- Research and development expenses increased to $1.9 million for the three months ended December 31, 2024, compared to $0.6 million for the same period in 2023.
- General and administrative expenses increased to $2.0 million for the three months ended December 31, 2024, compared to $0.7 million for the same period in 2023.
Risks
- The company's ability to continue as a going concern is uncertain due to recurring losses and the need for additional financing.
- The successful development and commercialization of product candidates are subject to numerous risks and uncertainties.
- The company may not be able to raise additional funds or enter into agreements when needed on favorable terms, or at all.
- The company is dependent on key members of management, and changes in personnel could impact operations.
Future Outlook
The company expects to continue to incur significant expenses and increasing operating losses for at least the next several years and believes its cash of $4.9 million at December 31, 2024 will fund its projected operations into July 2025.
Management Comments
- We believe that SON-1010 has the potential to complement that activity by activating the NK and T cells in the TME to secrete more interferon-gamma (IFN), which is considered to be important for anti-tumor control.
Industry Context
The company operates in the competitive biotechnology industry, focusing on oncology and cytokine-based therapies. The collaboration with Roche and Alkem demonstrates the company's ability to attract partnerships with established pharmaceutical companies.
Comparison to Industry Standards
- It's difficult to provide a direct comparison to industry standards without specific details on the clinical trial phases and specific therapeutic areas.
- However, similar companies in the biotechnology sector, such as BioNTech and Moderna, have demonstrated the potential for significant revenue generation through successful product development and commercialization.
- Sonnet's reliance on external funding and the need for additional capital are common challenges for clinical-stage biotechnology companies.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Chief Financial Officer | Jay Cross | Donald Griffith | February 21, 2025 | Resignation |
| Chief Business Officer | Stephen McAndrew | Stephen McAndrew | February 17, 2025 | Appointment |
Stakeholder Impact
- Shareholders: Dilution from potential equity offerings.
- Employees: Potential impact from cost-cutting measures or changes in management.
- Customers: Potential for new therapies if product candidates are successfully developed and commercialized.
- Creditors: Risk associated with the company's ability to repay debt.
Next Steps
- Continue clinical trials for product candidates.
- Pursue additional collaborations and partnerships.
- Seek regulatory approval for product candidates.
- Submit the IND for SON-1210 in Q1 calendar year 2025.
- Initiate Phase 2 trial for SON-080 in H2 calendar year 2025.
Key Dates
| Date | Description |
|---|---|
| 2012-07-31 | Discovery Collaboration Agreement with XOMA (US) LLC |
| 2015-04-06 | Sonnet BioTherapeutics, Inc. (Prior Sonnet) was incorporated as a New Jersey corporation |
| 2019-01-31 | Entered into a Frame Services and License Agreement (the Cellca Agreement) with Sartorius Stedim Cellca GMBH (Cellca) |
| 2020-04-01 | Prior Sonnet completed a merger with publicly-held Chanticleer Holdings, Inc. (Chanticleer) |
| 2021-12-01 | Entered into a Research and Development Agreement (the Navigo Agreement) with Navigo Proteins GmbH (Navigo) |
| 2022-04-01 | First milestone achieved in April 2022, at which time the Company incurred a $ 0.5 million license fee which was recorded as acquired in-process research and development. |
| 2023-01-01 | 9,175 restricted stock units (RSUs) and 7,977 restricted stock awards (RSAs) were granted, 100 % of which vested on January 1, 2025. |
| 2023-02-01 | Sonnet announced the successful completion of two IND-enabling toxicology studies with SON-1210 in non-human primates. |
| 2023-10-26 | Closed a public offering of common stock and certain warrants through Chardan and Ladenburg Thalmann & Co. Inc. as underwriters, for net proceeds of $ 3.9 million |
| 2024-05-02 | Entered into the Purchase Agreement and a Registration Rights Agreement (the Registration Rights Agreement), each with Chardan, related to a ChEF, Chardans committed equity facility, or the Facility |
| 2024-08-01 | Entered into a Master Clinical Collaboration Agreement (the SOC Agreement) with the Sarcoma Oncology Center (SOC) to advance the development of SON-1210. |
| 2024-09-30 | Effected a reverse stock split of its issued and outstanding common stock at a ratio of 1-for-8 (the Reverse Stock Split). |
| 2024-10-08 | Entered into a license agreement (the Alkem Agreement) with Alkem Laboratories Limited (Alkem) for the development and commercialization of SON-080 in DPN and/or CIPN in India. |
| 2024-11-07 | Closed a public offering of common stock and certain warrants through Chardan, as underwriter, for net proceeds of $ 4.2 million |
| 2024-12-10 | Closed a registered direct offering with institutional investors for the issuance and sale of 768,000 shares of its common stock, pre-funded warrants to purchase up to 317,325 shares of common stock, and accompanying warrants to purchase up to an aggregate of 1,085,325 shares of its common stock. |
| 2024-12-31 | Cash balance of $4.9 million. |
| 2025-01-01 | The total number of shares authorized under the Plan increased to 120,302. |
| 2025-01-22 | The European Patent Office granted our Patent No. EP3583125 B1, entitled Albumin Binding Domain Fusion Proteins, which covers our FHAB technology and includes therapeutic fusion proteins that utilize FHAB for tumor targeting and retention, and provide extended pharmacokinetics (PK). |
| 2025-02-10 | Jay Cross submitted his resignation as our Chief Financial Officer, effective February 21, 2025. |
| 2025-02-12 | Donald Griffith, CPA, our current Controller and a member of our Board, to succeed Mr. Cross as our Chief Financial Officer effective February 21, 2025. |
| 2025-02-12 | Stephen McAndrew, Ph.D., our Senior Vice President of Business Development, was appointed by our Board as our Chief Business Officer. |
| 2025-02-21 | Effective date of Donald Griffith as Chief Financial Officer. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.